Cecilia Carpio

2.0k total citations
55 papers, 774 citations indexed

About

Cecilia Carpio is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Cecilia Carpio has authored 55 papers receiving a total of 774 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pathology and Forensic Medicine, 26 papers in Oncology and 21 papers in Genetics. Recurrent topics in Cecilia Carpio's work include Lymphoma Diagnosis and Treatment (26 papers), Chronic Lymphocytic Leukemia Research (19 papers) and CAR-T cell therapy research (19 papers). Cecilia Carpio is often cited by papers focused on Lymphoma Diagnosis and Treatment (26 papers), Chronic Lymphocytic Leukemia Research (19 papers) and CAR-T cell therapy research (19 papers). Cecilia Carpio collaborates with scholars based in Spain, United States and Palestinian Territory. Cecilia Carpio's co-authors include Francesc Bosch, Pau Abrisqueta, Marta Crespo, Noelia Purroy, Carlos Palacio, Gloria Iacoboni, Josep Castellví, Pere Barba, Sabela Bobillo and Marc Simó and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Cecilia Carpio

47 papers receiving 769 citations

Peers

Countries citing papers authored by Cecilia Carpio

Since Specialization

Citations

This map shows the geographic impact of Cecilia Carpio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cecilia Carpio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cecilia Carpio more than expected).

Fields of papers citing papers by Cecilia Carpio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cecilia Carpio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cecilia Carpio. The network helps show where Cecilia Carpio may publish in the future.

Co-authorship network of co-authors of Cecilia Carpio

This figure shows the co-authorship network connecting the top 25 collaborators of Cecilia Carpio. A scholar is included among the top collaborators of Cecilia Carpio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cecilia Carpio. Cecilia Carpio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders 2025 ·Blood Advances ·(unknown), Vı́ctor Navarro, Moraima Jiménez, (unknown), Marc Bosch, (unknown), (unknown), Adaia Albasanz‐Puig, Isabel Ruíz-Camps, Cristina Andrés, Andrés Antón, Juliana Esperalba, (unknown), (unknown), Cecilia Carpio, Marta Crespo, Gloria Iacoboni, Ana Marín‐Niebla, Francesc Bosch, (unknown)	1
2	Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies 2024 ·Clinical Kidney Journal ·(unknown), Gloria Iacoboni, Sheila Bermejo, Cecilia Carpio, (unknown), Clara García-Carro, (unknown), (unknown), Oriol Bestard, Pere Barba, María José Soler	12
3	Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab 2024 ·Blood ·Gottfried von Keudell, Eliza A. Hawkes, Cecilia Carpio, Max S. Topp, (unknown), Jingjin Li, (unknown), (unknown), Hesham Mohamed, Srikanth Ambati, Aafia Chaudhry, Sabarish Ayyappan	0
4	Dynamics of Complete Responses in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab in the ELM-2 Study 2024 ·Blood ·Sabarish Ayyappan, H. Miles Prince, Cecilia Carpio, Isidro Jarque, Srikanth Ambati, (unknown), Hesham Mohamed, Giovanni Antico, (unknown), Jan Walewski	0
5	Impact of COVID‐19 infection on bispecific antibodies treatment in patients diagnosed with B‐cell lymphoproliferative disorders 2023 ·Hematological Oncology ·(unknown), (unknown), Moraima Jiménez, Alba Cabirta, (unknown), Isabel Ruíz-Camps, Cristina Andrés, Andrés Antón, Juliana Esperalba, (unknown), Cecilia Carpio, Marta Crespo, Sabela Bobillo, Gloria Iacoboni, Ana Marín‐Niebla, Francesc Bosch, Pau Abrisqueta	1
6	OPEN‐LABEL PHASE 1/2 STUDY OF CC‐99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL) 2023 ·Hematological Oncology ·Jean‐Marie Michot, Julio C. Chávez, Cecilia Carpio, Emmanuel Bachy, Silvia Ferrari, Franck Morschhauser, Judit Jørgensen, Raúl Córdoba, Pierre Bories, Poliana Patah, (unknown), Soraya Carrancio, (unknown), Xin Xiao Zheng, Mei Chen, Michael Pourdehnad, Loretta J. Nastoupil	0
7	ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2 2023 ·Hematological Oncology ·Michelle Poon, Jan Walewski, (unknown), (unknown), Isidro Jarque, Elżbieta Iskierka‐Jazdzewska, H. Miles Prince, Sung Yong Oh, Francesca Lim, Cecilia Carpio, Tran‐Der Tan, Sabarish Ayyappan, Antonio Gutiérrez, (unknown), Melanie Ufkin, Min Zhu, (unknown), Hesham Mohamed, Srikanth Ambati, W. S. Kim	5
8	Síndrome de Guillain-Barré y trombocitopenia tras la vacunación contra el SARS-CoV-2 con Moderna. Descripción de un caso 2022 ·Revista de Neurología ·Carlos Lázaro, Arnau Llauradó, (unknown), Alba Cabirta, Cecilia Carpio, (unknown), María Salvadó, N. Raguer, Juan Luis Restrepo‐Vera, (unknown)	2
9	Impact of Cytomegalovirus Replication in Patients with Aggressive B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy 2022 ·Transplantation and Cellular Therapy ·(unknown), Gloria Iacoboni, Berta Pernas, Juliana Esperalba, Ibai Los‐Arcos, Vı́ctor Navarro, (unknown), Francisco Beas, Adaia Albasanz‐Puig, Cecilia Carpio, Pere Barba, Isabel Ruíz-Camps	30
10	Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma 2022 ·Annals of Hematology ·Carmen Martı́nez, (unknown), (unknown), Antonio Gutiérrez, Eva Domingo‐Doménech, Ana Pilar González, (unknown), (unknown), (unknown), Cecilia Carpio, Mariana Bastos‐Oreiro, José‐Ángel Hernández‐Rivas, (unknown), (unknown), (unknown), (unknown), Arturo Pereira, Ramón García‐Sánz, (unknown)	5
11	Real-World Evidence of Brexucabtagene Autoleucel for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma 2021 ·Blood ·Gloria Iacoboni, Kai Rejeski, (unknown), Annalisa Chiappella, (unknown), Lucía López‐Corral, Mariana Bastos‐Oreiro, (unknown), Christian Schmidt, Cecilia Carpio, Juan Luís Reguera, Mi Kwon, Alejandro Martı́n, Pier Luigi Zinzani, Paolo Corradini, Marion Subklewe, Pere Barba	7
12	Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy 2021 ·Annals of Hematology ·Gloria Iacoboni, Marc Simó, Guillermo Villacampa, Eva Catalá, Cecilia Carpio, Cándido Díaz‐Lagares, Ángela Vidal‐Jordana, Sabela Bobillo, Ana Marín‐Niebla, (unknown), Moraima Jiménez, Pau Abrisqueta, Francesc Bosch, Pere Barba	41
13	Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain 2020 ·Biology of Blood and Marrow Transplantation ·Carmen Martı́nez, Cecilia Carpio, Inmaculada Heras, Eduardo Ríos, (unknown), Antonio Gutiérrez, (unknown), (unknown), Irene García-García, (unknown), (unknown), Joan Bargay, Cristina Barrenetxea, Eva Domingo‐Doménech, (unknown), Luis Palomera, Ramón García‐Sánz	18
14	Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation 2020 ·Translational Oncology ·Brendan P. Hodkinson, Michael Schäffer, Joshua Brody, Wojciech Jurczak, Cecilia Carpio, Dina Ben‐Yehuda, Irit Avivi, Ann Forslund, Muhıt Özcan, John Alvarez, (unknown), Nele Fourneau, Anas Younes, Sriram Balasubramanian	14
15	Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL) 2019 ·Blood ·Pau Abrisqueta, Juan‐Manuel Sancho, Raúl Córdoba, Daniel O. Persky, Charalambos Andreadis, Scott F. Huntington, Cecilia Carpio, (unknown), Xin Wei, Ying Fei Li, Marlene Zuraek, Michael R. Burgess, Kristen Hege, Alejandro Martı́n	29
16	Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts 2017 ·Blood ·Jason Kaplan, Leo I. Gordon, Alessandro Rambaldi, Giuseppe Gritti, Rakesh Popat, Howard A. Burris, Manish R. Patel, Sumit Madan, Ian Chau, John Radford, Swaminathan P. Iyer, Jaime Pérez de Oteyza, Pier Luigi Zinzani, Shining Wang, Emily Sheldon‐Waniga, (unknown), Yaping Shou, Cecilia Carpio, Francesc Bosch	1
17	Xpo-1 Inhibition Synergizes with BCR Inhibition, Blocks Tumor Growth and Tumor-Associated Macrophages Infiltration and Prolongs Survival in a Bioluminescent Animal Model of Primary Central Nervous System Lymphoma 2017 ·Blood ·Marta Crespo, (unknown), (unknown), Sabela Bobillo, Pau Abrisqueta, Carlos Palacio, Juan C. Nieto, (unknown), Cecilia Carpio, Josep Castellví, Joan Seoane, Francesc Bosch	2
18	Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia 2017 ·Scientific Reports ·(unknown), Cecilia Carpio, Pau Abrisqueta, (unknown), Noelia Purroy, (unknown), Carlos Palacio, Francesc Bosch, Marta Crespo	29
19	ZAP-70 Promotes the Infiltration of Malignant B-Lymphocytes into the Bone Marrow by Enhancing Signaling and Migration after CXCR4 Stimulation 2013 ·PLoS ONE ·(unknown), Noelia Purroy, Cecilia Carpio, Pau Abrisqueta, (unknown), Carlos Palacio, Josep Castellví, Marta Crespo, Francesc Bosch	13
20	YM155, a Small-Molecule Survivin Suppressant, Mainly Targets Primary CLL Cells Actively Proliferating and Overcomes Microenvironment-Mediated CLL Cell Protection 2012 ·Blood ·Noelia Purroy, Pau Abrisqueta, (unknown), Cecilia Carpio, Carlos Palacio, Laura Gallur, Marta Crespo, Francesc Bosch	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact